[go: up one dir, main page]

WO2008091870A3 - Pharmaceutical compositions comprising atorvastatin and nicotinic acid - Google Patents

Pharmaceutical compositions comprising atorvastatin and nicotinic acid Download PDF

Info

Publication number
WO2008091870A3
WO2008091870A3 PCT/US2008/051662 US2008051662W WO2008091870A3 WO 2008091870 A3 WO2008091870 A3 WO 2008091870A3 US 2008051662 W US2008051662 W US 2008051662W WO 2008091870 A3 WO2008091870 A3 WO 2008091870A3
Authority
WO
WIPO (PCT)
Prior art keywords
atorvastatin
nicotinic acid
pharmaceutical compositions
powder mixture
granulated powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/051662
Other languages
French (fr)
Other versions
WO2008091870A2 (en
Inventor
Magesh Kumar Devaraj
Vijayraghavan Thiruyur Panchanathan
Raja Kumar Seshadri
Venkata Nookaraju Sreedharala
Suman Sharma Ghati Sathyanarayana
Ratish Sashidharan Acharya
Raghava Raju Thummala Veera
Harish Kasam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Inc
Original Assignee
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Reddys Laboratories Ltd, Dr Reddys Laboratories Inc filed Critical Dr Reddys Laboratories Ltd
Priority to EA200970708A priority Critical patent/EA200970708A1/en
Publication of WO2008091870A2 publication Critical patent/WO2008091870A2/en
Publication of WO2008091870A3 publication Critical patent/WO2008091870A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A solid pharmaceutical dosage form comprises a granulated powder mixture comprising atorvastatin or a salt thereof and a granulated powder mixture comprising nicotinic acid or a derivative thereof. The present invention further encompasses stabilized pharmaceutical compositions of atorvastatin or its salts and nicotinic acid or its derivatives.
PCT/US2008/051662 2007-01-24 2008-01-22 Pharmaceutical compositions comprising atorvastatin and nicotinic acid Ceased WO2008091870A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EA200970708A EA200970708A1 (en) 2007-01-24 2008-01-22 PHARMACEUTICAL COMPOSITIONS INCLUDING ATORVASTATIN AND NICOTINIC ACID

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN153/CHE/2007 2007-01-24
IN153CH2007 2007-01-24
US94686707P 2007-06-28 2007-06-28
US60/946,867 2007-06-28

Publications (2)

Publication Number Publication Date
WO2008091870A2 WO2008091870A2 (en) 2008-07-31
WO2008091870A3 true WO2008091870A3 (en) 2009-01-22

Family

ID=39409972

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/051662 Ceased WO2008091870A2 (en) 2007-01-24 2008-01-22 Pharmaceutical compositions comprising atorvastatin and nicotinic acid

Country Status (2)

Country Link
EA (1) EA200970708A1 (en)
WO (1) WO2008091870A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2341773A4 (en) * 2008-09-24 2012-03-07 Merck Sharp & Dohme PHARMACEUTICAL COMPOSITIONS OF ATORVASTATIN
US20190105278A1 (en) * 2016-04-19 2019-04-11 Conaris Research Institute Ag Shellac microcapsule formulations and compositions
US20210275513A1 (en) * 2016-04-19 2021-09-09 Conaris Research Institute Ag Shellac microcapsule formulations and compositions for topical intestinal delivery of vitamin b3

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006046A1 (en) * 1997-07-31 1999-02-11 Kos Pharmaceuticals, Inc. Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia
EP1642593A1 (en) * 2003-06-06 2006-04-05 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006046A1 (en) * 1997-07-31 1999-02-11 Kos Pharmaceuticals, Inc. Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia
EP1642593A1 (en) * 2003-06-06 2006-04-05 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation

Also Published As

Publication number Publication date
WO2008091870A2 (en) 2008-07-31
EA200970708A1 (en) 2010-02-26

Similar Documents

Publication Publication Date Title
WO2008013838A3 (en) Pyridizinone derivatives
WO2010078486A3 (en) Opioid-containing oral pharmaceutical compositions and methods
WO2009024889A3 (en) Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
WO2007096151A3 (en) Inhibitors of p38-kinase for treatment of pulmonary hypertension
WO2007085833A3 (en) Pyrimidine derivatives
WO2010065709A3 (en) Hydroxamic acid derivatives, preparation and therapeutic uses thereof
WO2010114405A3 (en) Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
WO2008119825A3 (en) Imidazolidine carboxamide derivatives as p2x7 modulators
IL189375A (en) 1-heterocyclylsulfonyl-3-aminomethyl, 5-(hetero)aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments
WO2007090882A3 (en) Pharmaceutical extended release compositions comprising pramipexole
WO2007146248A3 (en) Stable laquinimod preparations
WO2006082523A3 (en) Pharmaceutical sustained release composition of metformin
WO2009024611A3 (en) 4-benzylaminoquinolines, pharmaceutical compositions containing them and their use
WO2009016498A8 (en) Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions
WO2007099216A3 (en) β-CRYSTALLINE FORM OF PERINDOPRIL ARGININE SALT, METHOD FOR MAKING SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
WO2007090749A3 (en) Benzamide and heteroarene derivatives as cetp inhibitors
WO2008062476A3 (en) Pharmaceutical composition comprising rosuvastatin or pharmaceutically accepatble salts thereof
IL181827A0 (en) Donepezil salts suitable for the preparation of pharmaceutical compositions
WO2011155793A3 (en) Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof
WO2008119685A3 (en) Oxazolidine and morpholine carboxamide derivatives as p2x7 modulators
WO2008001201A3 (en) Pharmaceutical compositions of clopidogrel
WO2007090661A3 (en) Active substance combination comprising azolylcarbinol compounds
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2007110834A3 (en) Malate salts, and polymorphs of (3s,5s)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid
WO2010070677A3 (en) A process for the preparation of prasugrel and its pharmaceutically acceptable salts thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08728043

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 4400/CHENP/2009

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 200970708

Country of ref document: EA

122 Ep: pct application non-entry in european phase

Ref document number: 08728043

Country of ref document: EP

Kind code of ref document: A2